Stock Traders Buy High Volume of Heron Therapeutics Put Options (NASDAQ:HRTX)

Posted by Geri Gentry on Oct 16th, 2026

Heron Therapeutics, Inc. (NASDAQ:HRTX – Get Free Report) saw some unusual options trading on Wednesday. Stock traders bought 41,908 put options on the stock. This is an increase of 7,201% compared to the typical daily volume of 574 put options.

Analysts Set New Price Targets

A number of equities analysts have weighed in on HRTX shares. Zacks Research raised Heron Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, August 3rd. Weiss Ratings restated a “sell (e+)” rating on shares of Heron Therapeutics in a research note on Friday, July 17th. Wall Street Zen raised shares of Heron Therapeutics to a “sell” rating in a report on Saturday, August 8th. Finally, HC Wainwright downgraded shares of Heron Therapeutics from a “buy” rating to a “neutral” rating in a report on Tuesday, August 11th. One research analyst has rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $2.00.

Check Out Our Latest Stock Report on HRTX

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. R Squared Ltd bought a new stake in shares of Heron Therapeutics during the 1st quarter valued at $27,000. HORAN Wealth LLC purchased a new stake in shares of Heron Therapeutics in the 1st quarter worth $33,000. Ieq Capital LLC purchased a new stake in shares of Heron Therapeutics in the 2nd quarter worth $41,000. Deutsche Bank AG purchased a new stake in shares of Heron Therapeutics in the 2nd quarter worth $41,000. Finally, Caitong International Asset Management Co. Ltd raised its holdings in Heron Therapeutics by 335.2% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 35,106 shares of the biotechnology company’s stock worth $46,000 after purchasing an additional 27,040 shares during the period. 80.01% of the stock is currently owned by institutional investors.

Heron Therapeutics Price Performance

Shares of NASDAQ:HRTX opened at $0.38 on Friday. The firm’s 50 day moving average price is $0.33 and its 200-day moving average price is $0.56. Heron Therapeutics has a twelve month low of $0.26 and a twelve month high of $1.57. The company has a quick ratio of 1.51, a current ratio of 2.49 and a debt-to-equity ratio of 24.35. The stock has a market capitalization of $71.48 million, a PE ratio of -1.98 and a beta of 1.62.

Heron Therapeutics (NASDAQ:HRTX – Get Free Report) last posted its quarterly earnings data on Monday, August 10th. The biotechnology company reported ($0.03) earnings per share (EPS) for the quarter. The business had revenue of $37.67 million during the quarter, compared to analysts’ expectations of $42.19 million. Heron Therapeutics had a negative return on equity of 293.02% and a negative net margin of 22.52%. Equities research analysts expect that Heron Therapeutics will post -0.14 EPS for the current year.

About Heron Therapeutics

(Get Free Report)

Heron Therapeutics, Inc is a commercial-stage biotechnology company focused on developing and commercializing medicines for acute care and oncology-related supportive care. The company’s products are designed to address patient needs in areas such as postsurgical pain and chemotherapy-induced nausea and vomiting.

Heron’s portfolio includes ZYNRELEF, an extended-release solution combining bupivacaine and meloxicam for the management of postsurgical pain, and APONVIE, an injectable formulation of aprepitant used to help prevent postoperative nausea and vomiting.